Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/28913
Title: CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer
Authors: Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.
Uludağ Üniversitesi/İktisadi ve İdari Bilimler Fakültesi/Ekonometri Bölümü.
Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
0000-0001-5492-184X
0000-0002-9732-5340
0000-0002-3820-424X
0000-0001-7904-883X
0000-0002-1619-6680
0000-0002-5956-8755
0000-0002-9038-0515
0000-0002-4483-9284
Tunca, Berrin
Egeli, Ünal
Çeçener, Gülşah
Tezcan, Gülçin
Gökgöz, Şehsuvar
Taşdelen, İsmet
Bayram, Nuran
Tolunay, Şahsine
Umut, Görkem
Demirdöğen, Elif
Ertürk, Elif
Ak, Seçil
Çetintaş, Sibel
Evrensel, Türkkan
AAG-9068-2021
AAA-7047-2020
AAH-3843-2020
AAJ-1027-2021
AAP-9988-2020
AAH-1420-2021
ABI-6078-2020
AAI-1612-2021
F-8554-2017
6602965754
55665145000
6508156530
25650627600
6603238737
9637821500
13609585600
6602604390
37058220200
25644460900
50261655300
55253485700
6505881756
6603942124
Keywords: Oncology
Breast cancer
Circulating tumor cells
Prognosis
Rna-positive cells
Polymerase-chain-reaction
Mammaglobin messenger-rna
Transcription-pcr assay
Peripheral-blood
Colorectal-cancer
Molecular-detection
Prognostic value
Rt-pcr
Adjuvant chemotherapy
Issue Date: 2012
Publisher: Sage Publications
Citation: Tunca, B. vd. (2012). "CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer". Tumori Journal, 98(2), 243-251.
Abstract: Aims and background. The major cause of death in breast cancer patients is metastasis. Various biomarkers have been used for the early detection of circulating tumor cells in the peripheral blood of breast cancer patients. The aims of the current study were to analyze circulating tumor cells in the blood of breast cancer patients by investigating EGFR, CK19, CK20 and HER2 expression profiles and to evaluate their prognostic importance. Methods. CK19, CK20 and EGFR gene expression profiles were evaluated in the blood samples of 84 female patients with primary invasive ductal breast cancer and 20 healthy female volunteers using SYBR green-based real-time qPCR assays. HER2 expression analyses were conducted in 46 patients who had an HER2-positive primary tumor and in 30 healthy women to determine the cutoff level of positivity. Results. The positive rates of CK20, EGFR, CK19 and HER2 mRNA expression in the peripheral blood were 28.57% (24/84), 20.23% (17/84), 5.95% (5/84) and 2.17% (1/46), respectively. The high positive ratio of CK20 mRNA expression in the peripheral blood of breast cancer was identified for the first time in the current study. Significant differences were identified in CK20 expression status and several clinical parameters related with aggressiveness of tumors using a binary logistic regression analysis. Higher CK20-positive levels were observed in patients who had lymph node metastasis and advanced-grade primary tumors, which were estrogen receptor-negative. We have demonstrated that CK20 may be a novel biomarker that is useful to identify circulating tumor cells and predict breast cancer progression. Conclusions. The results suggest that the investigation of CK20 mRNA with other biomarkers in the peripheral blood of breast cancer patients may be useful to monitor the presence of disseminated tumor cells in the blood circulation and to predict the prognosis of breast cancer.
URI: https://doi.org/10.1177/030089161209800211
https://journals.sagepub.com/doi/10.1177/030089161209800211
http://hdl.handle.net/11452/28913
ISSN: 0300-8916
2038-2529
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.